Company Overview - Axogen, Inc. (NASDAQ: AXGN) is a leader in developing and marketing surgical solutions aimed at restoring peripheral nerve function [3] - The company focuses on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] - Axogen's mission is to help restore peripheral nerve function and improve the quality of life for patients with nerve damage through innovative and clinically proven solutions [3] Product Portfolio - Axogen's product offerings include: - **Avance Nerve Graft**: A processed human nerve allograft for bridging severed peripheral nerves [4] - **Axoguard Nerve Connector**: An extracellular matrix coaptation aid for tensionless repair of severed nerves [4] - **Axoguard Nerve Protector**: A product used to wrap and protect damaged nerves while minimizing soft tissue attachments [4] - **Axoguard HA+ Nerve Protector™**: A next-generation technology designed to enhance nerve gliding and provide protection for peripheral nerve injuries [4] - **Axoguard Nerve Cap**: A product to protect nerve ends and reduce the development of painful neuromas [4] - **Avive+ Soft Tissue Matrix™**: An amniotic membrane allograft used to protect and separate tissues during healing [4] - The product portfolio is available in multiple countries including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [4] Upcoming Investor Conferences - Axogen management is scheduled to participate in several investor conferences: - **Cantor Global Healthcare Conference**: Fireside chat on September 3, 2025 [1] - **Wells Fargo Healthcare Conference**: 1x1 investor meetings on September 4, 2025 [2] - **Morgan Stanley Annual Global Healthcare Conference**: 1x1 investor meetings on September 10, 2025 [2] - **Lake Street Best Ideas Growth (BIG 9) Conference**: 1x1 investor meetings on September 11, 2025 [2] - Webcast events will be accessible live and archived for 90 days on Axogen's investor page [2]

Core Viewpoint - Fusion Fuel Green PLC will release an Investor Update Presentation and Video on September 17, 2025, to provide updates on financial results and strategic developments [1][2]. Company Overview - Fusion Fuel Green PLC (NASDAQ: HTOO) specializes in integrated energy engineering, distribution, and green hydrogen solutions through its Al Shola Gas and BrightHy Solutions platforms [3]. - The company operates in the LPG supply and hydrogen solutions sectors, supporting decarbonization across industrial, residential, and commercial sectors [3]. - Fusion Fuel is headquartered in Ireland and has operations in Europe and the Middle East [3]. Upcoming Events - The Investor Update Presentation and Video will be available on the company's Investors page on its website [2]. - Management will discuss updates on the company's activities in Al Shola Gas and BrightHy Solutions, along with other strategic developments [2].

Core Viewpoint - GD Culture Group Limited is set to launch an AI Immersive Reading Platform that aims to revolutionize storytelling by making it interactive and personalized, allowing readers to shape narratives and engage with characters in new ways [1][2][4]. Group 1: Platform Features - The AI Immersive Reading Platform transforms traditional storytelling into an interactive experience, enabling readers to choose story directions, interact with characters, and personalize story elements [2]. - The platform offers AI-driven tools for creators, simplifying the writing process and facilitating the development of adaptive story scripts [3]. Group 2: Business Model and Community Engagement - Stories published on the platform will be available through a subscription model that shares revenue with creators, fostering a sustainable ecosystem for creativity [3]. - The company is building a community of creators to explore the future of storytelling, inviting storytellers, writers, and game designers to participate and gain early access to tools and resources [4]. Group 3: Company Overview - GD Culture Group Limited operates primarily through its subsidiaries, including AI Catalysis Corp, and plans to enter the livestreaming market focused on e-commerce [6].

Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with I ...

Core Insights - DaVita Clinical Research (DCR) has been instrumental in advancing kidney care over the past 25 years, focusing on new therapies, clinical outcomes, and the future of nephrology through rigorous research and clinical trials [1][2][3] Research Contributions - DCR has authored 180 manuscripts and 520 research abstracts or posters aimed at improving clinical outcomes in kidney care and related diseases [4] - A 2017 study demonstrated that ClearGuard HD antimicrobial barrier caps significantly reduce bloodstream infections in dialysis patients, leading to improved outcomes [5] - Upcoming research will be presented at the American Society of Nephrology Kidney Week, highlighting the association between GLP-1 drugs and hospitalization rates for kidney failure patients [6] Clinical Trials and Innovations - DCR is the largest U.S. trial network for chronic kidney disease (CKD) and end-stage kidney disease (ESKD), conducting impactful trials efficiently [7] - DaVita contributed to COVID-19 vaccine trials and supported vaccination efforts for at-risk patients, showcasing its commitment to public health [8] - The company has implemented decentralized recruitment services to enhance diversity in clinical trials, addressing barriers faced by dialysis patients [9] Company Overview - As of June 30, 2025, DaVita served approximately 283,100 patients across 3,175 outpatient dialysis centers, with 2,662 centers in the U.S. and 513 in 13 other countries [11] - DaVita has conducted over 500 clinical trials across more than 250 research sites, engaging directly with every ESKD drug approved by the FDA [12]

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: Wells Fargo Healthcare Conference, Boston, MA: Fireside chat on Wednesday, September 3 at 9:30 am ETCantor Global Healthcare Conference – New York, NY: Fireside chat on Thursday, September 4 at ...

Core Viewpoint - DeFi Technologies Inc. has launched eight new SEK-denominated exchange-traded products (ETPs) through its subsidiary Valour, expanding its offerings in the Nordic market and providing regulated access to various digital assets [1][10]. Summary by Category New Product Launch - Valour has introduced eight new ETPs on Sweden's Spotlight Stock Market, including Valour Shiba Inu (SHIB), Valour Pi (PI), Valour Ondo (ONDO), Valour Cronos (CRO), Valour Mantle (MNT), Valour VeChain (VET), Valour Ethena (ENA), and Valour Celestia (TIA) [1][10]. - Each ETP offers regulated, exchange-traded exposure to its underlying digital asset via traditional brokerage accounts, with a management fee of 1.9% [2]. Product Details - Valour Shiba Inu (SHIB) is a community token with an expanding ecosystem [3]. - Valour Pi (PI) is the native token of the Pi Network, aimed at inclusive crypto access [4]. - Valour Ondo (ONDO) focuses on tokenized real-world assets and on-chain yield distribution [5]. - Valour Cronos (CRO) supports payments, DeFi, and consumer applications on an EVM-compatible blockchain [6]. - Valour Mantle (MNT) serves as the governance token for a high-throughput Ethereum Layer-2 ecosystem [7]. - Valour VeChain (VET) targets enterprise use cases like supply-chain visibility [8]. - Valour Ethena (ENA) is a governance token for a synthetic-dollar and yield infrastructure protocol [9]. - Valour Celestia (TIA) is the native token of a modular blockchain network providing data-availability layers [10]. Market Position and Strategy - With over 85 ETPs listed across major European exchanges, Valour is reinforcing its leadership in regulated digital-asset investment solutions [10][14]. - The new listings cater to growing investor demand for diversified digital-asset exposure, covering various blockchain layers and real-world asset infrastructures [10][13]. - Executives from Valour emphasize the importance of providing simple and transparent access to a wider range of digital assets, aligning with market demand [13][14].

Company Overview - NanoXplore Inc. is a graphene company that manufactures and supplies high-volume graphene powder for transportation and industrial markets [3] - The company provides standard and custom graphene-enhanced plastic and composite products to various sectors including transportation, packaging, and electronics [3] - NanoXplore also manufactures silicon-graphene enhanced Li-ion batteries for Electric Vehicle and grid storage markets [3] - The company is headquartered in Montreal, Quebec, with manufacturing facilities across North America and Europe [3] Upcoming Financial Events - NanoXplore will hold a webcast to discuss its fourth quarter and year-end results for the period ending June 30, 2025, on September 17, 2025, at 10:00 a.m. Eastern Time [1][2] - The financial results will be released on September 16, 2025, after market close [1]

Delivers 11th consecutive quarter of growth, with record net sales of $1.2 billion, up 7% from last year, exceeding outlookNet sales growth led by Americas up 8%, APAC up 12%, partially offset by 1% decline in EMEAHollister brands delivers its best ever second quarter net sales on growth of 19%, with Abercrombie brands down 5%Second quarter operating margin of 17.1% and earnings per share of $2.91 include a litigation settlement benefit of $39 million on pre-tax basis, $0.59 per share benefit on tax-adjuste ...

RYE, N.Y., Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of GAMCO Natural Resources, Gold & Income Trust (NYSE:GNT) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions. The Board of Trustees declared cash distributions of $0.05 per share for each of October, November, and December 2025. Based on current dynamics, the Fund may make distributions in excess of the Fund’s earnings. It is currently expected that distributions to common shareholders in 2025 will pri ...